A multicenter, observational study to evaluate the safety of restarting antitumor therapy recovered from COVID-19.

ABSTRACT:

Aims

Cancer patients face a higher risk of adverse effects from coronavirus disease 2019 (COVID-19) compared to the general population. However, the safety of restarting antitumor therapy following COVID-19 recovery remains unclear.

Methods

In this prospective, multicenter study conducted between January 1 and 30 March 2023, 419 eligible cancer patients who had recovered from COVID-19 were screened across four medical centers. The primary endpoint was the incidence of treatment-emergent adverse events (TEAEs) during the first cycle of antitumor therapy resumed within 3 months after COVID-19 recovery. Changes in clinical laboratory parameters were assessed as secondary endpoints.

Results

A total of 270 eligible participants were included in this study. The common grade

SUBMITTER: Guo L 

PROVIDER: S-EPMC12773609 | biostudies-literature | 2026 Jan

REPOSITORIES: biostudies-literature